DMRA Damora Therapeutics Inc.

Price (delayed)

$30.39

Market cap

$1.88B

P/E Ratio

4.06

Dividend/share

N/A

EPS

$7.49

Enterprise value

$1.34B

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: 74
Relative Profitability: Rel. Profitability: 0
Highlights
DMRA's EPS has surged by 157% year-on-year and by 42% since the previous quarter
Damora Therapeutics's debt has plunged by 100% YoY
The quick ratio has contracted by 12% from the previous quarter
DMRA's net income is down by 12% since the previous quarter

Key stats

What are the main financial stats of DMRA

DMRA stock price

How has the Damora Therapeutics stock price performed over time
Intraday
-0.75%
1 week
-6.32%
1 month
5.45%
1 year
805.22%
YTD
32.07%
QTD
16.84%

Financial performance

How have Damora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$270.66M
Net income
-$262.83M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 13% QoQ
DMRA's net income is down by 12% since the previous quarter

Price vs fundamentals

How does DMRA's price correlate with its fundamentals

Growth

What is Damora Therapeutics's growth rate over time

Valuation

What is Damora Therapeutics stock price valuation
P/E
4.06
P/B
3.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DMRA's EPS has surged by 157% year-on-year and by 42% since the previous quarter
DMRA's price to book (P/B) is 113% more than its last 4 quarters average of 1.7

Efficiency

How efficient is Damora Therapeutics business performance
The return on assets has increased by 32% since the previous quarter and by 18% year-on-year
Damora Therapeutics's ROE has increased by 32% from the previous quarter and by 24% YoY

Dividends

What is DMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMRA.

Financial health

How did Damora Therapeutics financials performed over time
Damora Therapeutics's total liabilities has increased by 16% from the previous quarter
The quick ratio has contracted by 12% from the previous quarter
Damora Therapeutics's debt is 100% less than its equity
The debt to equity has plunged by 100% YoY
Damora Therapeutics's debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.